Marker Therapeutics (MRKR) Return on Equity (2016 - 2025)
Marker Therapeutics (MRKR) has disclosed Return on Equity for 11 consecutive years, with 0.99% as the latest value for Q3 2025.
- On a quarterly basis, Return on Equity fell 121.0% to 0.99% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.99%, a 121.0% decrease, with the full-year FY2024 number at 0.66%, down 100.0% from a year prior.
- Return on Equity was 0.99% for Q3 2025 at Marker Therapeutics, up from 1.17% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.38% in Q4 2023 to a low of 1.17% in Q2 2025.
- A 5-year average of 0.5% and a median of 0.62% in 2021 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: surged 118bps in 2023, then plummeted -121bps in 2025.
- Marker Therapeutics' Return on Equity stood at 0.82% in 2021, then grew by 25bps to 0.61% in 2022, then soared by 162bps to 0.38% in 2023, then tumbled by -317bps to 0.82% in 2024, then decreased by -21bps to 0.99% in 2025.
- Per Business Quant, the three most recent readings for MRKR's Return on Equity are 0.99% (Q3 2025), 1.17% (Q2 2025), and 0.77% (Q1 2025).